Sonnet Biotherapeutics Holdings Stock Retained Earnings
| SONN Stock | USD 2.90 0.02 0.68% |
Sonnet Biotherapeutics Holdings fundamentals help investors to digest information that contributes to Sonnet Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Sonnet Stock. The fundamental analysis module provides a way to measure Sonnet Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sonnet Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -57.1 M | -60 M | |
| Retained Earnings Total Equity | -51.4 M | -54 M |
Sonnet | Retained Earnings |
Sonnet Biotherapeutics Holdings Company Retained Earnings Analysis
Sonnet Biotherapeutics' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Sonnet Biotherapeutics Retained Earnings | (110.24 M) |
Most of Sonnet Biotherapeutics' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sonnet Biotherapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sonnet Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Sonnet Biotherapeutics is extremely important. It helps to project a fair market value of Sonnet Stock properly, considering its historical fundamentals such as Retained Earnings. Since Sonnet Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sonnet Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sonnet Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Sonnet Biotherapeutics Holdings has a Retained Earnings of (110.24 Million). This is 111.84% lower than that of the Biotechnology sector and 213.78% lower than that of the Health Care industry. The retained earnings for all United States stocks is 101.18% higher than that of the company.
Sonnet Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sonnet Biotherapeutics' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sonnet Biotherapeutics could also be used in its relative valuation, which is a method of valuing Sonnet Biotherapeutics by comparing valuation metrics of similar companies.Sonnet Biotherapeutics is currently under evaluation in retained earnings category among its peers.
Sonnet Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Sonnet Biotherapeutics from analyzing Sonnet Biotherapeutics' financial statements. These drivers represent accounts that assess Sonnet Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Sonnet Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 36.3M | 193.5M | 118.9M | 51.0M | 23.8M | 34.4M | |
| Enterprise Value | 46.1M | 186.5M | 91.4M | 48.2M | 21.7M | 43.8M |
Sonnet Biotherapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sonnet Biotherapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sonnet Biotherapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Sonnet Fundamentals
| Return On Equity | -2.65 | ||||
| Return On Asset | -0.97 | ||||
| Operating Margin | (219.69) % | ||||
| Current Valuation | (958.18 K) | ||||
| Shares Outstanding | 837.66 K | ||||
| Shares Owned By Insiders | 4.22 % | ||||
| Shares Owned By Institutions | 1.10 % | ||||
| Number Of Shares Shorted | 66.23 K | ||||
| Price To Book | 0.93 X | ||||
| Price To Sales | 43.77 X | ||||
| Revenue | 147.81 K | ||||
| Gross Profit | (21.09 M) | ||||
| EBITDA | (18.72 M) | ||||
| Net Income | (18.83 M) | ||||
| Cash And Equivalents | 5.22 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 203.91 K | ||||
| Debt To Equity | 0.36 % | ||||
| Current Ratio | 1.10 X | ||||
| Book Value Per Share | 4.01 X | ||||
| Cash Flow From Operations | (21.34 M) | ||||
| Short Ratio | 1.44 X | ||||
| Earnings Per Share | (0.96) X | ||||
| Target Price | 240.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | 1.05 | ||||
| Market Capitalization | 2.45 M | ||||
| Total Asset | 5.43 M | ||||
| Retained Earnings | (110.24 M) | ||||
| Working Capital | (786.37 K) | ||||
| Net Asset | 5.43 M |
About Sonnet Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sonnet Biotherapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sonnet Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sonnet Biotherapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Sonnet Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonnet Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonnet Biotherapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonnet Biotherapeutics Holdings Stock: Check out Sonnet Biotherapeutics Piotroski F Score and Sonnet Biotherapeutics Altman Z Score analysis. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.96) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.